CATX Stock — Perspective Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.88

Market cap

$328.8M

Cash

$236.9M

Enterprise value

$93.5M

Balance sheet

Cash	$236.9M
Debt	$1.6M
Net cash	$235.3M
Enterprise value	$93.5M
Basic shares	114.1M shares
Fully diluted shares	125.0M shares
Fully diluted market cap	$360.0M
Cash per share	$2.08

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CATX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 24	[203Pb]VMT01	Phase 1/2	Recurrent Melanoma (Skin); Metastatic Melanoma; Melanoma Stage IV	—
Mar 13 - Apr 24	[203Pb]Pb-PSV359	Phase 1/2	Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Esophageal Cancer	—
Jan 7 - Feb 18	[203Pb]VMT-α-NET	Phase 1/2	Neuroendocrine Tumors Unresectable; Neuroendocrine Tumor Metastatic; Gastroenteropancreatic Neuroendocrine Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Bamzireotide navoxetan

Phase 1 · Active Modality: radiopharmaceutical (targeted alpha therapy)

Aliases [212Pb]VMT-α-NET, VMT-α-NET

Target SSTR2 (somatostatin receptor type 2)

Partnerships Lantheus: option agreement (Jan 2024) — $28.0M one-time payment for exclusive option to negotiate worldwide royalty/milestone-bearing license to [212Pb]VMT-α-NET; right to co-fund IND-enabling studies for early PSMA/GRPR candidates

Indications

Neuroendocrine tumors (SSTR2-positive, unresectable or metastatic) (Phase 1)
Meningioma (SSTR2+, LEMONαDE cohort) (Phase 1)

Catalysts

— October 23, 2026

Status note Multi-center open-label dose-escalation/dose-expansion study (NCT05636618); 76 NET patients across four cohorts + 1 meningioma patient treated as of Jul 31, 2026. EC orphan medicinal product designation for gastroenteropancreatic NETs granted Jul 2026. Advancing toward Phase 3 in NETs with site activation targeted around year-end 2026.

Lapemelanotide zapixetar

Phase 1 · Active Modality: radiopharmaceutical (targeted alpha therapy)

Aliases [212Pb]VMT01, VMT01

Target MC1R (melanocortin 1 receptor)

Partnerships Bristol Myers Squibb: clinical trial collaboration (Mar 2024) evaluating VMT01 + nivolumab

Indications

Unresectable or metastatic melanoma (MC1R-positive) (Phase 1)

Catalysts

— late 2026

Status note Phase 1/2a dose-escalation/dose-expansion study (NCT05655312), monotherapy and + nivolumab cohorts. FDA Fast Track granted Sep 2024 for diagnosis/treatment of MC1R-expressing unresectable/metastatic melanoma.

PSV359

Phase 1 · Active Modality: radiopharmaceutical (targeted alpha therapy)

Aliases [212Pb]PSV359

Target FAP-α (fibroblast activation protein alpha)

Indications

Solid tumors (FAP-α expressing) (Phase 1)

Catalysts

— 2027

Status note Novel cyclic peptide (phage display) conjugated to Pb-specific chelator. IND cleared Q1 2025; 17 patients treated across three cohorts as of Jul 31, 2026; Cohort 3 (6.0 mCi q8w) fully enrolled Q2 2026.

PSV594

Preclinical · Active Modality: radiopharmaceutical (targeted alpha therapy)

Target CCK2R (cholecystokinin 2 receptor)

Indications

CCK2R-expressing cancers (Preclinical)

Status note First-in-human imaging presented May 2026; pre-IND development supported by preclinical + biodistribution data.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	[203Pb]VMT01
Lead indication	Recurrent Melanoma (Skin)
Lead phase	Phase 1/2
Active trials	3
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05655312	Phase 1/2	Recruiting	Sponsor	Perspective Therapeutics	—	Recurrent Melanoma (Skin); Metastatic Melanoma; Melanoma Stage IV	—
NCT06710756	Phase 1/2	Recruiting	Sponsor	Perspective Therapeutics	—	Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Esophageal Cancer	—
NCT05636618	Phase 1/2	Recruiting	Sponsor	Perspective Therapeutics	—	Neuroendocrine Tumors Unresectable; Neuroendocrine Tumor Metastatic; Gastroenteropancreatic Neuroendocrine Tumor	—
NCT06148636	Early Phase 1	Active, not recruiting	Collaborator	David Bushnell	—	Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1	—
NCT05111509	Early Phase 1	Active, not recruiting	Collaborator	Yusuf Menda	—	Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor Grade 1	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Perspective Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,210,117	+460,782	0.19%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CATX — Perspective Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders